Related Experiment Video
Updated: Jul 5, 2026

Assay Development for High-Throughput Drug Screening Against Mycobacteria
Published on: October 25, 2024
Oritavancin: a potential weapon in the battle against serious Gram-positive pathogens
Jared Crandon1, David P Nicolau
1Center for Anti-Infective Research & Development, Hartford Hospital, 80 Seymour Street, Hartford, CT 06102, USA. jcrandon@harthosp.org
Abstract:
Oritavancin is a lipoglycopeptide antibiotic with activity against aerobic and anaerobic Gram-positive bacteria. Oritavancin separates itself from other glycopeptides through its potent in vitro activity against resistant isolates of Staphylococcus aureus, Enterococcus spp. and Streptococcus spp. Oritavancin possesses a long half-life that should allow, at maximum, once-daily dosing. Currently, oritavancin has completed two Phase III trials and one Phase II trial for the treatment of complicated skin and skin structure infections, and two Phase II trials for the treatment of Gram-positive bacteremia. In all instances, oritavancin displayed favorable outcomes and was noninferior to comparator agents (vancomycin followed by oral cephalexin) when a comparison was made. Further studies are necessary to fully characterize dose and clinical role.
Related Concept Videos
Antimicrobial Effectiveness
Antibiotic Selection
Inhibitors of Gram-positive Cell Wall Synthesis
Development of Antibiotic Resistance
Clinical Significance of Antibiotic Resistance
Inhibitors of Bacterial Protein Synthesis
